Skip to Main Content
Upcoming Events / Principled Engineering: AI and Drug Development
  • Virtual

Principled Engineering: AI and Drug Development

Where

Virtual

When

{{getUserDateTimeZone("1646265600").singleDate}}
{{getUserDateTimeZone("1646265600").time}} - {{getUserDateTimeZone("1646269200").time}} {{getClientTimeZoneName()}}

About

The use of artificial intelligence in drug discovery, when coupled with new genetic insights and the increase of patient medical data of the last decade, has the potential to bring novel medicines to patients more efficiently and more predictably. Join us for a discussion of the promise and potential pitfalls of relying on AI in bringing life-saving drugs to market — and an exploration of questions of justice and equity in drug research and access.

Our speakers will be Russ Altman, Stanford professor of bioengineering, genetics, medicine, and biomedical data science, in conversation with Kim Branson, global head of AI and machine learning at GSK. Jack Fuchs, an adjunct lecturer who teaches “Principled Entrepreneurial Decisions” at Stanford School of Engineering, will moderate and explore how clearly articulated principles can guide the direction of technological advancements like AI-enabled drug discovery.

View the live stream information for this event here

Register Now

Host

  • Stanford University School of Engineering

More events in "Biotech"

San Francisco, CA [email protected]: What’s Next For Biotech?

It was only two years ago when it felt as if biotech had saved the world — and then, a year later, ended up in a prolonged slump. We&#